Expa
3DBio is a clinical-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and materials technologies to deliver safe, functional and personalized living tissues and organs, engineered on-demand for patients. 3DBio’s pioneering approach develops living tissue implants with structural and functional integrity with a four-part technology platform, including: novel and proprietary 3D-bioprinter (GMPrint™), bio-ink (ColVivo™), specialized cell culture system, and
Basic Information
- Category: Venture Capital
- Founded: 2013
- Headquarters: San Francisco, CA
- Website: expa.com
Documented Facts
- Email: hello@expa.com (No linked source recorded for this statement.)
Evidence and Sources
- Expa — Official Site (official)
Citation Guidance
Explore Venture Capital profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Expa.
- Canonical profile: https://brandsource.ai/brands/expa
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/expa/json-ld
- Citation profile API: https://brandsource.ai/api/brands/expa/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T03:57:27.394Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
3DBio is a clinical-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and materials technologies to deliver safe, functional and personalized living tissues and organs, engineered on-demand for patients. 3DBio’s pioneering approach develops living tissue implants with structural and functional integrity with a four-part technology platform, including: novel and proprietary 3D-bioprinter (GMPrint™), bio-ink (ColVivo™), specialized cell culture system, and
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.